Pacira BioSciences, Inc.
PCRX
$24.45
$1.054.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -9.79% | 11.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -9.79% | 11.08% | |||
| Cost of Revenue | -42.70% | 10.03% | |||
| Gross Profit | 7.21% | 11.63% | |||
| SG&A Expenses | 9.00% | 7.10% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.14% | 7.57% | |||
| Operating Income | -73.50% | 34.55% | |||
| Income Before Tax | -65.89% | 118.38% | |||
| Income Tax Expenses | -58.95% | 105.75% | |||
| Earnings from Continuing Operations | -70.00% | 111.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -70.00% | 111.18% | |||
| EBIT | -73.50% | 34.55% | |||
| EBITDA | -42.90% | 20.32% | |||
| EPS Basic | -70.06% | 111.17% | |||
| Normalized Basic EPS | -66.10% | 34.06% | |||
| EPS Diluted | -69.82% | 110.65% | |||
| Normalized Diluted EPS | -64.18% | 26.23% | |||
| Average Basic Shares Outstanding | 0.23% | 0.08% | |||
| Average Diluted Shares Outstanding | -5.12% | 6.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||